GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DiaMedica Therapeutics Inc (NAS:DMAC) » Definitions » 5-Day RSI

DMAC (DiaMedica Therapeutics) 5-Day RSI : 52.05 (As of Dec. 13, 2024)


View and export this data going back to 2007. Start your Free Trial

What is DiaMedica Therapeutics 5-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-12-13), DiaMedica Therapeutics's 5-Day RSI is 52.05.

The industry rank for DiaMedica Therapeutics's 5-Day RSI or its related term are showing as below:

DMAC's 5-Day RSI is ranked worse than
88.98% of 1525 companies
in the Biotechnology industry
Industry Median: 41.75 vs DMAC: 52.05

Competitive Comparison of DiaMedica Therapeutics's 5-Day RSI

For the Biotechnology subindustry, DiaMedica Therapeutics's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DiaMedica Therapeutics's 5-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's 5-Day RSI distribution charts can be found below:

* The bar in red indicates where DiaMedica Therapeutics's 5-Day RSI falls into.



DiaMedica Therapeutics  (NAS:DMAC) 5-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DiaMedica Therapeutics  (NAS:DMAC) 5-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


DiaMedica Therapeutics 5-Day RSI Related Terms

Thank you for viewing the detailed overview of DiaMedica Therapeutics's 5-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


DiaMedica Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Executives
Jan Stahlberg 10 percent owner C/O TRILL INVEST AB, SVEAVAGEN 17 FL 18, STOCKHOLM V7 SE 111 57
Koch Thomas Von 10 percent owner TOMENTERPRISE AB, BOX 5322, STOCKHOLM V7 102 47
Scott Kellen officer: CFO and Secretary 3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Randall Michael Giuffre director 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Ab Trill 10 percent owner SVEAVAGEN 17, 18TH FLOOR, STOCKHOLM V7 SE-11157
Richard D. Pilnik director 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Dietrich John Pauls director, officer: President and CEO 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Ii Jacinto 10 percent owner 394 SADDLE BACK TRAIL, FRANKLIN LAKES NJ 07417
David J. Wambeke officer: Chief Business Officer 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305
Private Ab Tomeqt 10 percent owner C/O KINKON AB, BIBLIOTEKSGATAN 25, STOCKHOLM V8 11435
Ab Tomenterprise 10 percent owner C/O EQT PARTNERS AB, BOX 16509, STOCKHOLM V7 103 27
Charles Pauling Semba director TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Kuntz director MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Tanya Lewis director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Julie Vanorsdel Daves officer: SVP Clinical Development Oper. 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305